Predictive value of plasma volume status for contrast-induced nephropathy in patients with heart failure undergoing PCI

Chen He1, Sicheng Zhang2, Haoming He2, Zhebin You1, Xueqin Lin2, Liwei Zhang2, Jiankang Chen1* and Kaiyang Lin2*

1Department of Geriatric Medicine, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fujian Key Laboratory of Geriatrics, Fujian Provincial Center for Geriatrics, Fuzhou, 350001, China; and 2Department of Cardiology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fujian Provincial Key Laboratory of Cardiovascular Disease, Fuzhou, Fujian 350001, China

Abstract

Aims Contrast-induced nephropathy remains a common complication of coronary procedure and increases poor outcomes, especially in patients with heart failure. Plasma volume expansion relates to worsening prognosis of heart failure. We hypothesized that calculated plasma volume status (PVS) might provide predictive utility for contrast-induced nephropathy in patients with heart failure undergoing elective percutaneous coronary intervention (PCI).

Methods and results We enrolled 441 patients with heart failure undergoing elective PCI from 2012 to 2018. Pre-procedural estimated PVS by the Duarte’s formula (Duarte-ePVS) and Kaplan–Hakim formula (KH-ePVS) were calculated for all patients. CIN was defined as an absolute serum creatinine (SCr) increase ≥0.5 mg/dL or a relative increase ≥25% compared with the baseline value within 48 h of contrast medium exposure. We assessed the association between PVS and CIN in patients with heart failure undergoing elective PCI. In 441 patients, 28 (6.3%) patients developed CIN. The median Duarte-ePVS was 4.44 (3.87, 5.13) and the median KH-ePVS was 0.03 (0.09, 0.05). The best cutoff values for Duarte-ePVS and KH-ePVS to predict CIN were 4.64 (with 78.6% sensitivity and 61.7% specificity) and 0.04 (with 64.5% sensitivity and 75.5% specificity), respectively. After adjusting for potential confounding variables, KH-ePVS > 0.04 [odds ratio (OR) 2.685, 95% confidence interval (CI) 1.012–7.123, P = 0.047] remained significantly associated with CIN whereas Duarte-ePVS was not.

Conclusions Pre-procedural KH-ePVS is an independent risk factor for CIN in patients with heart failure undergoing elective PCI. The best cutoff point of KH-ePVS for predicting CIN was 0.04.

Keywords Plasma volume status; Contrast-induced nephropathy; Heart failure; Elective percutaneous coronary intervention

Received: 1 July 2021; Revised: 23 September 2021; Accepted: 5 October 2021

© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Introduction

Contrast-induced nephropathy (CIN) is a common complication following administration of iodinated contrast media (CM) during angiography or other medical procedures, which is one of the leading causes of nosocomial acute renal failure.1,2 It is associated with increased morbidity, mortality, length of hospitalization, and acceleration towards end-stage renal disease.3–5 Heart failure is a well-known risk factor for CIN,3,6,7 but patients with heart failure cannot receive adequate hydration because fluid overload may worsen heart failure. Therefore, novel markers of plasma volume expansion might better stratify risk and guide hydration in patients with heart failure.

Plasma volume expansion is a significant complication which predicts poor prognosis in patients with heart failure.8
It can manifest with haemodynamic congestion and peripheral and pulmonary oedema but is difficult to quantify non-invasively. Tracer-dilution techniques can measure plasma volume optimally but have not been readily available to clinicians because they are costly, time consuming and complex. Recent studies showed calculated estimates of plasma volume status (PVS), which derived from a routine blood count and/or body weight, was moderately-to-highly correlated with the directly measured plasma volume and had prognostic value for heart failure. However, the relationship between PVS and CIN in patients with heart failure undergoing elective percutaneous coronary intervention (PCI) has not been evaluated. The purpose of our study is to explore the predictive value of PVS on CIN in patients with heart failure undergoing elective PCI.

Method

Study population

We conducted a retrospective, single-centre observational study, enrolling consecutive patients with heart failure undergoing elective PCI at Fujian Provincial Hospital in China from January 2012 to December 2018. Exclusion criteria were (i) lacking anyone of the data on haematocrit, haemoglobin, weight and pre-procedural or post-procedural serum creatinine (SCr) levels; (ii) estimated glomerular filtration rate (eGFR) <15 mL/min/1.73 m² or dialysis; (iii) iodic contrast medium administration during the preceding 7 days; (iv) cancer with expectation of life less than 1 year; (v) died within 24 h after procedure; (vi) allergy to contrast medium.

Protocol

Haematocrit, haemoglobin and body weight were measured for each patient at admission and SCr was measured at admission and daily for the 2 days after contrast exposure. Data including baseline demographic, comorbidities, clinical risk factors, clinical treatment, and laboratory results were drawn from medical records. Elective PCI was performed by experienced interventional cardiologists and medication use was determined by clinicians according to current guidelines. The low-osmolar, non-ionic CM (either Iopamiron or Ultravist, both 370 mg I/mL) was administered during all procedures. Hydration therapy was at the clinician’s discretion, and all patients received 0.9% normal saline (at a rate of 0.5 mL/kg/h) for 12 h during perioperative period except those who were intolerant. The study protocol was approved by the ethics committee of the Fujian Provincial Hospital, China (ethics approval number: K2019-07-011).

Plasma volume equations

The PVS was calculated in all study participants using both the Duarte’s formula and Kaplan–Hakim formula. Estimated plasma volume assessed by the Duarte’s formula (Duarte-ePVS) was calculated as follows: Duarte-ePVS = [(1 − haematocrit)/(haemoglobin)] × 100, measured in the unit of decilitres per gram (dL/g).

Estimated plasma volume assessed by Kaplan–Hakim formula (KH-ePVS) was calculated by comparing actual plasma volume (aPV) to ideal plasma volume (iPV). The aPV was calculated by following equation incorporating haematocrit and weight derived from curve-fitting techniques:

\[
aPV = (1 - \text{haematocrit}) \times [a + (b \times \text{body weight})]
\]

\[
(a = 1530 \text{ in males and } a = 864 \text{ in females,} \\
b = 41.0 \text{ in males and } b = 47.9 \text{ in females}).
\]

The iPV was calculated by following equation:

\[
iPV = c \times \text{body weight \ (c = 39 in males and c = 40 in females)}. \]

Therefore, relative PVS which reflecting the degree to which patients have deviated from their ideal plasma volume was calculated by following equation:

\[
KH - ePVS = |(aPV–iPV)/iPV| \times 100%.
\]

Definition and study endpoint

The primary endpoint in the study was incidence of CIN, defined as an absolute SCr increase ≥0.5 mg/dL or a relative increase in serum creatinine ≥25% compared with the baseline value within 48 h of contrast medium exposure. Additional endpoint was long-term mortality. The diagnosis of heart failure was based on the presence of appropriate symptoms (e.g. orthopnoea) and signs (e.g. bilateral oedema, increased jugular venous pressure), elevated level of brain natriuretic peptide (BNP) or N-terminal pro B-type natriuretic peptide (NT-proBNP), and a left ventricular ejection fraction (LVEF) ≤50%. Anaemia was defined as haematocrit <0.39 (for male patients) or <0.36 (for female patients). The eGFR was calculated using the modified modification of diet in renal disease equation: 186.3 × SCr-1.154 × (age in years) – 0.203 × 1.212 (if patient was black) × 0.742 (if patient was female).

Statistical analysis

All data were analysed with SPSS 25.0. The baseline characteristics were compared between two groups divided by CIN. Data are presented as mean ± standard deviation (SD) for normally distributed continuous variables, or medians.
and interquartile ranges for unevenly distributed continuous variables. The Student’s t test or Wilcoxon rank sum test was performed to determine the differences between groups. The categorical variables were represented as percentages and compared by chi-square test or Fisher exact test. Risk factors were initially screened for univariate association with CIN, and variables with P < 0.20 were then entered into a multivariate logistic analysis with forward stepwise algorithm. Multivariate logistic regression analysis was performed to identify independent risk factors for CIN. Receiver operator characteristic (ROC) curve analysis was performed to identify the optimal cutoff point for PVS to predict CIN. Areas under the curve (AUC) were calculated as measures of the accuracy of the test. The Kaplan–Meier curve assessed the survival between different estimated PVS groups (Duarte-ePVS > 4.64 vs. Duarte-ePVS ≤ 4.64 and KH-ePVS > 0.04 vs. KH-ePVS ≤ 0.04). A two-sided P value <0.05 was considered significant.

Results

Baseline characteristics

A total of 441 patients were included in this study, of whom 28 (6.3%) developed CIN. The median Duarte-ePVS was 4.44 (3.87, 5.13) and the median KH-ePVS was −0.03 (−0.09, 0.05). Baseline characteristics for patients with and without CIN are shown in Table 1. Patients with CIN were older, more

| Table 1 Baseline variables in patients with and without CIN |
|-------------------------------------------------------------|
| Demographics                                                |
| Age, years                                                  | 64.61 ± 11.42 | 64.13 ± 11.35 | 71.14 ± 10.45 | 0.001     |
| Sex, female, n (%)                                          | 87 (19.7%)     | 74 (17.9%)     | 13 (46.4%)    | <0.001    |
| BMI, kg/m²                                                   | 23.88 (21.37–26.11) | 23.88 (21.43–26.09) | 23.85 (20.53–27.25) | 0.810     |
| Systolic blood pressure, mmHg                               | 127.62 ± 21.32 | 127.57 ± 21.29 | 128.25 ± 22.10 | 0.854     |
| Diastolic blood pressure, mmHg                              | 74.29 ± 12.31  | 74.31 ± 12.30  | 73.93 ± 12.66  | 0.910     |
| Medical history                                             |
| Smoker, n (%)                                                | 223 (50.6%)    | 211 (51.1%)    | 12 (42.9%)     | 0.399     |
| Myocardial infarction, n (%)                                | 195 (44.2%)    | 177 (42.9%)    | 18 (63.6%)     | 0.027     |
| Hypertension, n (%)                                         | 278 (63.0%)    | 258 (62.5%)    | 20 (71.4%)     | 0.342     |
| Diabetes, n (%)                                             | 182 (41.3%)    | 172 (41.6%)    | 10 (35.7%)     | 0.537     |
| Atrial fibrillation, n (%)                                  | 53 (12.0%)     | 47 (11.4%)     | 6 (21.4%)      | 0.114     |
| Anaemia, n (%)                                              | 184 (41.7%)    | 163 (39.5%)    | 21 (75.0%)     | <0.001    |
| Medication                                                  |
| Antiplatelet agents, n (%)                                  | 440 (99.8%)    | 412 (99.8%)    | 28 (100.0%)    | 0.794     |
| Statin use, n (%)                                           | 434 (98.4%)    | 406 (98.3%)    | 28 (100.0%)    | 0.487     |
| ACEI/ARB, n (%)                                             | 372 (84.4%)    | 348 (84.3%)    | 24 (85.7%)     | 0.838     |
| β-blocker, n (%)                                            | 388 (88.0%)    | 363 (87.9%)    | 25 (89.3%)     | 0.826     |
| Diuretics, n (%)                                            | 278 (63.0%)    | 251 (60.8%)    | 27 (96.4%)     | <0.001    |
| Laboratory result                                           |
| NT-proBNP, pg/mL                                            | (426.00–3048.50) | (417.05–2870.50) | (2296.00–12046.75) | <0.001    |
| Creatinine, mg/dL                                          | 0.95 (0.81–1.10) | 0.94 (0.81–1.08) | 1.06 (0.84–1.40) | 0.032     |
| WBC, 10⁹/L                                                 | 7.10 (5.80–8.69) | 7.10 (5.80–8.55) | 7.20 (5.65–10.20) | 0.519     |
| HGB, g/L                                                   | 134.02 ± 17.62 | 135.02 ± 17.01 | 120.54 ± 20.34 | <0.001    |
| HCT                                                        | 0.40 ± 0.05     | 0.40 ± 0.05     | 0.36 ± 0.05     | <0.001    |
| Cholesterol, mmol/L                                        | 4.14 ± 1.11     | 4.13 ± 1.11     | 4.25 ± 1.11     | 0.646     |
| LDL-C, mmol/L                                              | 2.62 ± 1.05     | 2.61 ± 1.05     | 2.77 ± 0.98     | 0.502     |
| eGFR, mL/min/1.73 m²                                        | 83.45 ± 24.98   | 84.43 ± 24.52   | 70.27 ± 27.84   | 0.004     |
| eGFR < 60 mL/min/1.73 m², n (%)                             | 71 (16.1%)      | 60 (14.5%)      | 11 (39.3%)     | 0.001     |
| LVF, %                                                     | 42.25 ± 6.37    | 42.39 ± 6.26    | 40.34 ± 7.66   | 0.103     |
| KH-ePVS                                                    | −0.03 (−0.09–0.05) | −0.03 (−0.10–0.04) | 0.07 (−0.02–0.11) | <0.001 |
| Duarte-ePVS                                                | 4.44 (3.87–5.13) | 4.38 (3.86–5.04) | 5.12 (4.65–6.72) | <0.001 |

Procedure performed

Multi-vascular coronary artery disease, n (%)                | 379 (85.9%)     | 355 (86.0%)     | 24 (85.7%)     | 0.972     |
| Number of stents, n                                        | 1.67 ± 0.93     | 1.69 ± 0.93     | 1.43 ± 0.88    | 0.149     |
| Contrast volume, mL                                        | 194.14 ± 64.80  | 194.35 ± 63.93  | 191.25 ± 76.76 | 0.782     |
| Iso-omslar contrast media use, n (%)                       | 150 (34.0%)     | 138 (33.4%)     | 12 (42.9%)     | 0.307     |

Abbreviations: ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; BMI, body mass index; CIN, contrast induced nephropathy; NT-proBNP, N-terminal pro B type natriuretic peptide; HCT, haematocrit; HGB, haemoglobin; LDL-C, low-density lipoprotein; eGFR, estimated glomerular filtration rate; LVF, left ventricular ejection fraction; KH-ePVS, Kaplan–Hakim-estimated plasma volume status; Duarte-ePVS, Duarte-estimated plasma volume status; WBC, white blood cells.

DOI: 10.1002/ehf2.13681
likely to have myocardial infarction, anaemia, worse renal function, and higher levels of NT-proBNP, Duarte-ePVS, and KH-ePVS. A higher percentage of diuretics using during hospitalization was shown in patients who developed CIN (all $P < 0.05$).

**Receiver operator characteristic analysis and multivariable factors for predicting contrast-induced nephropathy**

According to the ROC curve analysis, the optimal cutoff value for KH-ePVS to predict CIN was measured as $>0.04$, with 64.5% sensitivity and 75.5% specificity, and the optimal cutoff value for Duarte-ePVS to predict CIN was measured as $>4.64$, with 78.6% sensitivity and 61.7% specificity [for KH-ePVS: C-statistic = 0.718; 95% confidence interval (CI) 0.674–0.760; for Duarte-ePVS: C-statistic = 0.720; 95% CI 0.618–0.823; Figure 1]. The rate of CIN was higher in patients with KH-ePVS $> 0.04$ (15.13% vs. 3.11%) and those with Duarte-ePVS $> 4.64$ (12.15% vs. 2.31%) than patients with lower estimated PVS (both $P < 0.001$, Figure 2A,B).

Results of multivariate logistic regression analysis have been displayed in Table 2. After adjusting for potential confounding risk factors including age $>75$ years, myocardial infarction, anaemia, lg (NT-proBNP) and eGFR <60 mL/min/1.73m², KH-ePVS $> 0.04$ remained significant independent predictor of CIN [odds ratio (OR) 2.685, 95% CI 1.012–7.123, $P = 0.047$], whereas there was no significant association between CIN and Duarte-ePVS either considered as a continuous ($P = 0.216$) or categorical variable ($P = 0.184$).

**Plasma volume status and long-term outcomes**

The median follow-up period was 637 days (interquartile range: 387 to 990 days). Compared with patients with KH-ePVS $< 0.04$, the Kaplan–Meier curve showed that patients with KH-ePVS $> 0.04$ had a higher rate of all-cause long-term mortality ($P = 0.028$; Figure 3A). Similarly, the cumulative
rate for all-cause death was higher in patients with Duarte-ePVS > 4.64 than those with Duarte-ePVS ≤ 4.64 (P = 0.035; Figure 3B).

**Discussion**

To the best of our knowledge, this is the first study that investigates the relationship between PVS and incidence of CIN. The present study showed that higher pre-procedural KH-ePVS, which obtained from Kaplan–Hakim formula was associated with increased risk of CIN in patients with heart failure undergoing elective PCI, and the best cutoff value for KH-ePVS to predict CIN was 0.04 with 64.5% sensitivity and 75.5% specificity according to the ROC analysis (C-statistic = 0.718; 95% CI, 0.674–0.760). Even after adjusting for potential confounding risk factors like myocardial infarction, anemia, age > 75 years, lg (NT-proBNP)
and eGFR < 60 mL/min/1.73 m², KH-ePVS > 0.04 was still an independent risk factor for predicting CIN markedly. However multivariate logistic analysis did not show association between Duarte-ePVS which obtained from Duarte’s formula and CIN. Meanwhile, in our study both KH-ePVS > 0.04 and Duarte-ePVS > 4.64 were associated with higher rate of long-term mortality.

Heart failure, as a known risk factor for CIN, has been included in the Mehran risk score for CIN.6,7 Worsened cardiac function contributes to adverse haemodynamic state and reduced renal blood flow, which stimulates the renin–angiotensin system and sympathetic nervous system, increasing levels of inflammatory factors and ROS, and consequently promoting the development of CIN.21,22 Plasma volume expansion is a significant complication in patients with heart failure and predicts poor prognosis.8 Although hydration is effective in preventing CIN, excessive plasma volume expansion might cause more harm than benefit in patients with heart failure.23,24 Therefore, it is significant to research the association between plasma volume and CIN in patients with heart failure.

Plasma volume is classically measured by Tracer-dilution techniques, but these methods are expensive, time consuming and complex.10,11 Estimated PVS, calculated from a routine blood count and/or body weight, has been validated as surrogate of intravascular filling using radiolabelled albumin.12,13 Prior studies have demonstrated the independent association between PVS and poor outcome, consistently and across a wide heart failure spectrum, regardless of the formula used.25 Duarte et al.14 put forward Duarte’s formula firstly and revealed prognostic value of Duarte-ePVS in the setting of heart failure complicating acute myocardial infarction. Subsequent researches further confirmed the association between Duarte-ePVS and poor outcome in patients with acute decompensated heart failure or chronic heart failure with preserved ejection fraction.15,26–29 Ling et al.13 found that KH-ePVS independently predicted death and first morbid events in chronic heart failure and KH-ePVS > −4% was associated with the worst prognosis. Similar prognostic value of KH-ePVS was shown in patients with acute heart failure syndromes30 or preserved ejection fraction.31 Furthermore, patients with a higher PVS often have poor renal function.13,31 A KH-ePVS ≥ 5.6% independently predicted greater postoperative renal complication in patients undergoing coronary artery bypass graft.32 Our study demonstrated the predictive value of PVS for CIN for the first time.

In fact, estimated PVS is also a congestion marker in patients with heart failure, which associated with E/e’ pulmonarv artery pressure,34 and BNP.31 Mullens et al. found venous congestion was the most important haemodynamic factor for worsening of renal function in advanced decompensated heart failure.35 Increased renal venous pressure from venous congestion reduces the arteriovenous gradient over renal circulation, increases renal interstitial pressure, and thereby impairs renal blood flow and destroy the architecture of the renal tissues, afterwards influencing local oxygen exchange and leading to diffuse metabolic dysfunction.35–37 This may be the mechanism by which ePVS was associated with CIN in patients with heart failure.

Although Duarte’s formula is now the dominating formula to calculate ePVS, it is KH-ePVS—not Duarte-ePVS—that showed predictive value for CIN in our study. Possible reasons for these differences in associations might rely on KH-ePVS incorporating body weight: KH-ePVS might reflect the degree to which patients have deviated from their ideal weight rather than a direct estimated measurement of plasma volume.

The findings of our study suggest the predictive value of PVS for CIN in patients with heart failure undergoing elective PCI, which is of great significance in clinical practice. Based on two readily available parameters, body weight and haematocrit, KH-ePVS can be calculated quickly to make effective measures taken for the certain higher-risk patients before procedure. Moreover, for the patients with KH-ePVS > 0.04, who suffer more from congestion, we suspect that hydration may not be a good strategy for preventing CIN and some decongestion treatment like diuresis may be better. The current study just puts forward consideration, and more prospective observational and interventional studies are needed to determine its value.
This study has some limitations. First, this study was a single-centre, observational study, with a relatively small sample size, which potentially limit the universality of the findings. Second, data on peri-procedural fluid intake and output are lacking, which may influence the incidence of CIN. Third, although we had adjusted for many confounding factors, the results may not be fully generalizable to other populations.
factors, there were still some potential confounders that cannot be controlled. Despite these limitations, our study revealed the association between volume expanding and CIN in patients with heart failure undergoing elective PCI, and provided novel insights into the PVS.

**Conclusions**

Pre-procedural PVS is an independent risk factor for CIN in patients with heart failure undergoing elective PCI. The best cutoff point for KH-ePVS to predict CIN was 0.04. These findings might guide use of preventive measures and therapy to prevent CIN.

**Acknowledgements**

This study was funded by a grant from the Joint funds for the innovation of science and technology, Fujian province (grant number: 2018Y9097), high-level hospital foster grants from Fujian Provincial Hospital, Fujian province, China (grant number: 2020HSJJ05), Fujian provincial health technology project (grant number: 2019-ZQN-10), Natural Science Foundation of Fujian Province (grant number: 2018J01256).

**Conflict of interest**

The authors have declared that no conflict of interest exists.

**Informed consent**

Informed consents were obtained from all participants included in the study.

**References**

1. Brigugori C, Tavano D, Colombo A. Contrast agent-associated nephrotoxicity. *Prog Cardiovasc Dis* 2003; 45: 493–503.
2. McCullough PA, Wolyn R, Rocher LL, Levin RN, O’Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. *Am J Med* 1997; 103: 368–375.
3. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, Leon MB, Dangas G. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. *J Am Coll Cardiol* 2004; 44: 1393–1399.
4. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M, Bell MR, Barness GW, Mathew V, Garrant KN, Holmes DR Jr. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. *Circulation* 2002; 105: 2259–2264.
5. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. *JAMA* 1996; 275: 1489–1494.
6. Balemans CE, Reichert LJ, van Schelven BI, van den Brand JA, Wetzels JF. Epidemiology of contrast material-induced nephropathy in the era of hydration. *Radiology* 2012; 263: 706–713.
7. Silver SA, Shah PM, Chertow GM, Harel S, Wald R, Harel Z. Risk prediction models for contrast induced nephropathy: systematic review. *BMJ* 2015; 351: h4395.
8. Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris PC. Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. *Circulation* 1989; 80: 299–305.
9. Kalra PR, Anagnostopoulos C, Bolger AP, Coats AJ, Anker SD. The regulation and measurement of plasma volume in heart failure. *J Am Coll Cardiol* 2002; 39: 1901–1908.
10. Gibson JG, Seligman AM. The distribution of red cells and plasma in large and minute vessels of the normal dog, determined by radioactive isotopes of iron and iodine. *J Clin Invest* 1946; 25: 848–857.
11. International Committee for Standardization in Haematology. Recommended methods for measurement of red-cell and plasma volume. *J Nucl Med.* 1980; 21: 793–800.
12. Fudim M, Miller WL. Calculated estimates of plasma volume in patients with chronic heart failure—comparison with measured volumes. *J Card Fail* 2018; 24: 553–560.
13. Ling HZ, Flint J, Damgaard M, Bonfils PK, Cheng AS, Aggarwal S, Velmurugan S, Mendonca M, Rashid M, Kang S, Papalia F, Weissert S, Coats CJ, Thomas M, Kuskowski M, Cohn JN, Woldman S, Anand IS, Okonko DO. Calculated plasma volume status and prognosis in chronic heart failure. *Eur J Heart Fail* 2015; 17: 35–43.
14. Duarte K, Monnez JM, Albuissous E, Pitt B, Zannad F, Rossignol P. Prognostic value of estimated plasma volume in heart failure. *JACC Heart Fail* 2015; 3: 886–893.
15. Kobayashi M, Rossignol P, Ferreira JP, Aragão I, Paku Y, Iwasaki Y, Watanabe M, Fudim M, Duarte K, Zannad F, Girerd N. Prognostic value of estimated plasma volume in acute heart failure in three cohort studies. *Clin Res Cardiol* 2019; 108: 549–561.
16. Hakim RM. Plasmapheresis. In Dougirdas J. T., Blake P. G., Ing T. S., eds. *Handbook of Dialysis*, 3rd ed. Philadelphia: LIPINCOTT, Williams and Wilkins; 2001. p 236.
17. Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J. *Body Fluids and other mass data.* Harrison’s *Principles of Internal Medicine*, 18th ed. New York: McGraw Hill; 2011. p A-1.
18. JNS, JRS, JCS Joint Working Group. Guidelines on the use of iodinated contrast media in patients with kidney disease 2012. *Circ J* 2013; 77: 1883–1914.
19. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Calk F, González-Juanatey JR, Harjola VP, Janikowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parisis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force Members, Document Reviewers. 2016 ESC guidelines

DOI: 10.1002/ehf2.13681
Predictive value of plasma volume status for contrast-induced nephropathy in patients with heart failure undergoing elective percutaneous coronary intervention

for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail* 2016; 18: 891–975.

20. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis* 2002; 39: S1–S266.

21. Azzalini L, Spagnoli V, Ly HQ. Contrast-induced nephropathy: from pathophysiology to preventive strategies. *Can J Cardiol* 2016; 32: 247–255.

22. Rosenstock JL, Gilles E, Geller AB, Panagopoulos G, Mathew S, Maleckal D, DeVita MV, Michelis MF. Impact of heart failure on the incidence of contrast-induced nephropathy in patients with chronic kidney disease. *Int Urol Nephrol* 2010; 42: 1049–1054.

23. Liu Y, Li H, Chen S et al. Excessively high hydration volume may not be associated with decreased risk of contrast-induced acute kidney injury after percutaneous coronary intervention in patients with renal insufficiency. *J Am Heart Assoc.* 2016; 5: e003171.

24. Bei WJ, Wang K, Li HL, Guo XS, Guo W, Abuduinai T, Chen SQ, Islam SMS, Chen PY, Chen JY, Liu Y, Tan N. Safe hydration to prevent contrast-induced acute kidney injury and worsening heart failure in patients with renal insufficiency and heart failure undergoing coronary angiography or percutaneous coronary intervention. *Int Heart J* 2019; 60: 247–254.

25. Kobayashi M, Girerd N, Duarte K, Chouihed T, Chikamori T, Pitt B, Zannad F, Rossignol P. Estimated plasma volume status in heart failure: clinical implications and future directions. *Clin Res Cardiol* 2021; 110: 1159–1172.

26. Kobayashi M, Girerd N, Duarte K, Preud’homme G, Pitt B, Rossignol P. Prognostic impact of plasma volume estimated from hemoglobin and hematocrit in heart failure with preserved ejection fraction. *Clin Res Cardiol* 2020; 109: 1392–1401.

27. Huang CY, Lin TT, Wu YF, Chiang FT, Wu CK. Long-term prognostic value of estimated plasma volume in heart failure with preserved ejection fraction. *Sci Rep* 2019; 9: 14369.

28. Balderston JR, Shah KB, Paciulli SC, Gertz ZM. Usefulness of estimated plasma volume at postdischarge follow-up to predict recurrent events in patients with heart failure. *Am J Cardiol* 2018; 122: 1191–1194.

29. Massari F, Sicchitano P, Iacovelli M, Passantino A, Guida P, Sanasi M, Piscopo A, Romito R, Valle R, Caldarola P, Ciccone MM. Multiparametric approach to congestion for predicting long-term survival in heart failure. *J Cardiol* 2020; 75: 47–52.

30. Yoshihisa A, Abe S, Sato Y, Watanabe S, Yokokawa T, Miura S, Misaka T, Sato T, Suzuki S, Oikawa M, Kobayashi A, Yamaki T, Kunii H, Saitoh SI, Takeishi Y. Plasma volume status predicts prognosis in patients with acute heart failure syndromes. *Eur Heart J Acute Cardiovasc Care* 2018; 7: 330–338.

31. Grodin JL, Philips S, Mullens W, Nijs P, Martens P, Fang JC, Dzavner MH, Tang WHW, Pandey A. Prognostic implications of plasma volume status estimates in heart failure with preserved ejection fraction: insights from TOPCAT. *Eur J Heart Fail* 2019; 21: 634–642.

32. Mazyczka AM, Barakat MF, Ussen B, Kaura A, Abu-Own H, Jouhra F, Jaumdally H, Amin-Youssef G, Nicou N, Baghai M, Deshpande R, Wendler O, Kolvekar S, Okonko DO. Calculated plasma volume status and outcomes in patients undergoing coronary bypass graft surgery. *Heart* 2019; 105: 1020–1026.

33. Kobayashi M, Huttin O, Donal E, Duarte K, Hubert A, Le Breton H, Galli E, Fournet M, Mabo P, Schnell F, Leclercq C, Rossignol P, Girerd N. Association of estimated plasma volume status with hemodynamic and echocardiographic parameters. *Clin Res Cardiol* 2020; 109: 1060–1069.

34. Almufleh A, Desai AS, Fay R, Ferreira JP, Buckley LF, Mehra MR, Rossignol P, Zannad F. Correlation of laboratory haemoconcentration measures with filling pressures obtained via pulmonary arterial pressure sensors in ambulatory heart failure patients. *Eur J Heart Fail* 2020; 22: 1907–1911.

35. Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Tang WHW. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. *J Am Coll Cardiol* 2009; 53: 589–596.

36. Damman K, Testani JM. The kidney in heart failure: an update. *Eur Heart J* 2015; 36: 1437–1444.

37. Prowle JR, Echeverri JE, Ligabo EV, Ronco C, Bellomo R. Fluid balance and acute kidney injury. *Nat Rev Nephrol* 2010; 6: 107–115.